5 Key Takeaways

• 1

  The FDA expanded the indication for efgartigimod to include all adults with generalized myasthenia gravis, regardless of antibody status.

• 2

  The approval encompasses patients who are AChR-Ab positive, MuSK-Ab positive, LRP4-Ab positive, and triple seronegative.

• 3

  The Phase 3 ADAPT SERON trial demonstrated significant improvement in MG-ADL scores for patients treated with efgartigimod compared to placebo.

• 4

  Efgartigimod showed a mean 3.35-point improvement in MG-ADL total score at week 4, with benefits observed across various antibody subgroups.

• 5

  The treatment was well tolerated, with common side effects including respiratory infections, headaches, and injection-site reactions.